FACTS ABOUT TRACLEER REVEALED

6 The phosphodiesterase-five inhibitor sildenafil is licensed for PAH in FC I–IV from the United states of america and FC II–III in Europe. Endothelin receptor antagonists (ERAs) together with bosentan, sitaxentan and ambrisentan are oral therapies certified for use in PAH. As no oral agent has revealed superiority there continues to be discuss